티로신키나아제 억제제 치료 후 발생한 중증 저칼슘혈증및 갑상선기능저하증 1례
A Case Report of Severe Hypocalcemia and Hypothyroidism after Tyrosine Kinase Inhibitor Treatment
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
After introducing tyrosine kinase inhibitors (TKIs) as promising treatments for radioactive iodine refractory advanced thyroid cancer patients, we more often meet patients with TKI-related hormone and electrolyte imbalances in clinics. Hypocalcemia associated with TKI is associated with an imbalance in calcium-vitamin D metabolism. TKI-related hypothyroidism is related to the metabolic rate of thyroid hormones. The two side effects usually occur in the early stages of TKI treatment, and if the imbalance is corrected appropriately, the effects are minor, but in severe cases, the TKI should be discontinued. The authors reported a case of severe hypocalcemia and thyroid dysfunction after TKI treatment. A 56-year-old man suffered from symptomatic hypocalcemia during TKI treatment, which was resolved after he stopped taking the TKI medication. Although calcium and vitamin D replacement have increased, hypocalcemia was recurred and TKI treatments have been permanently stopped due to serious weight loss in grade 3. After the interruption, his calcium levels normalized.
Abstract
After introducing tyrosine kinase inhibitors (TKIs) as promising treatments for radioactive iodine refractory advanced thyroid cancer patients, we more often meet patients with TKI-related hormone and electrolyte imbalances in clinics. Hypocalcemia associated with TKI is associated with an imbalance in calcium-vitamin D metabolism. TKI-related hypothyroidism is related to the metabolic rate of thyroid hormones. The two side effects usually occur in the early stages of TKI treatment, and if the imbalance is corrected appropriately, the effects are minor, but in severe cases, the TKI should be discontinued. The authors reported a case of severe hypocalcemia and thyroid dysfunction after TKI treatment. A 56-year-old man suffered from symptomatic hypocalcemia during TKI treatment, which was resolved after he stopped taking the TKI medication. Although calcium and vitamin D replacement have increased, hypocalcemia was recurred and TKI treatments have been permanently stopped due to serious weight loss in grade 3. After the interruption, his calcium levels normalized.
참고문헌 (23)
- Schlumberger M, "Lenvatinib versus placebo in radioiodinerefractory thyroid cancer", N Engl J Med, 372(7), pp.621~630 (2015)
- Brose MS, "Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial", Lancet, 384(9940), pp.319~328 (2014)
- Kawalec P, "Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib", Expert Rev Anticancer Ther, 16(12), pp.1303~1309 (2016)
- 이가희, "2016년 대한갑상선학회 갑상선결절 및 암 진료 권고안 개정안", International Journal of Thyroidology, 9(2), pp.59~126 (2016), 대한갑상선학회
- Haugen BR, "2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer", Thyroid, 26(1), pp.1~133 (2016)
- Motzer RJ, "Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial", Lancet Oncol, 16(15), pp.1473~1482 (2015)
- Dy GK, "Understanding, recognizing, and managing toxicities of targeted anticancer therapies", CA Cancer J Clin, 63(4), pp.249~279 (2013)
- Puzziello A, "Hypocalcemia following thyroid surgery: incidence and risk factors. A longitudinal multicenter study comprising 2,631 patients", Endocrine, 47(2), pp.537~542 (2014)
- 성지영, "갑상선 유두암 환자의 전절제술 후 부갑상선 기능 저하증의 위험 인자", Journal of Endocrine Surgery, 16(3), pp.70~78 (2016), 대한내분비외과학회
- Eismontas V, "Predictors of postoperative hypocalcemia occurring after a total thyroidectomy: results of prospective multicenter study", BMC Surg, 18(1), pp.55~ (2018)
- Roh JL, "Prevention of postoperative hypocalcemia with routine oral calcium and vitamin D supplements in patients with differentiated papillary thyroid carcinoma undergoing total thyroidectomy plus central neck dissection", Cancer, 115(2), pp.251~258 (2009)
- Bellini E, "Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism", Ann Oncol, 22(4), pp.988~990 (2011)
- Mir O, "Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications", Ann Oncol, 23(1), pp.280~281 (2012)
- Phillip V, "Influence of Sorafenib and Bevacizumab on pancreatic volume - A monocentric CT based analysis", Pancreatology, 16(4), pp.621~624 (2016)
- Porta C, "Renal effects of targeted anticancer therapies", Nat Rev Nephrol, 11(6), pp.354~370 (2015)
- Deininger MW, "Practical management of patients with chronic myeloid leukemia receiving imatinib", J Clin Oncol, 21(8), pp.1637~1647 (2003)
- Worden F, "Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer", Endocr Relat Cancer, 22(6), pp.877~887 (2015)
- Wong E, "Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity", Thyroid, 17(4), pp.351~355 (2007)
- Abdulrahman RM, "Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination", J Clin Endocrinol Metab, 95(8), pp.3758~3762 (2010)
- Kamba T, "VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature", Am J Physiol Heart Circ Physiol, 290(2), pp.H560~H576 (2006)
- Jean GW, "Toxic effects of sorafenib in patients with differentiated thyroid carcinoma compared with other cancers", JAMA Oncol, 2(4), pp.529~534 (2016)
- Verloop H, "Sorafenib therapy decreases the clearance of thyrotropin", Eur J Endocrinol, 168(2), pp.163~167 (2013)
- Schmidinger M, "Hypothyroidism in patients with renal cell carcinoma: blessing or curse?", Cancer, 117(3), pp.534~544 (2011)